Eldon C. Mayer III Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Eldon C. Mayer III.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Eldon C. Mayer III. Eldon C. Mayer III is EVP & Chief Commercial Officer in RIGEL PHARMACEUTICALS INC ($RIGL) and EVP &Chief Commercial Officer in RIGEL PHARMACEUTICALS INC ($RIGL) and Director in Eiger BioPharmaceuticals, Inc. ($EIGR) and Ex VP & Chief Commerc. Officer in Eiger BioPharmaceuticals, Inc. ($EIGR).
Latest Insider Trading Transactions of Eldon C. Mayer III
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Ex VP & Chief Comme ... | Option Exercise | A | 9.99 | 71,250 | 711,788 | 71,250 | |
| Mar 15 2021 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Ex VP & Chief Comme ... | Grant | A | 0.00 | 11,875 | 0 | 47,685 | 35.8 K to 47.7 K (+33.16 %) |
| Jan 11 2021 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Ex VP & Chief Comme ... | Sell | S | 11.68 | 1,690 | 19,739 | 35,810 | 37.5 K to 35.8 K (-4.51 %) |
| Jan 31 2020 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Ex VP & Chief Comme ... | Option Exercise | A | 12.36 | 150,000 | 1,854,000 | 150,000 | |
| Jan 31 2020 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Ex VP & Chief Comme ... | Grant | A | 0.00 | 7,500 | 0 | 37,500 | 30 K to 37.5 K (+25.00 %) |
| Jan 30 2020 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Ex VP & Chief Comme ... | Buy | P | 13.52 | 5,000 | 67,603 | 30,000 | 25 K to 30 K (+20.00 %) |
| Nov 20 2019 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Option Exercise | A | 4.49 | 75,000 | 336,750 | 75,000 | |
| Mar 25 2019 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Option Exercise | A | 13.41 | 10,000 | 134,100 | 10,000 | |
| Mar 25 2019 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Option Exercise | A | 13.41 | 10,000 | 134,100 | 10,000 | |
| Mar 22 2019 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Option Exercise | A | 4.49 | 75,000 | 336,750 | 75,000 | |
| Jan 25 2019 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Option Exercise | A | 2.00 | 200,000 | 400,000 | 200,000 | |
| Nov 30 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 10.21 | 4,000 | 40,840 | 25,000 | 21 K to 25 K (+19.05 %) |
| Nov 28 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 10.07 | 6,000 | 60,447 | 21,000 | 15 K to 21 K (+40.00 %) |
| Nov 28 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 10.07 | 6,000 | 60,447 | 21,000 | 15 K to 21 K (+40.00 %) |
| Nov 28 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 9.92 | 7,500 | 74,408 | 15,000 | 7.5 K to 15 K (+100.00 %) |
| Nov 28 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 9.92 | 7,500 | 74,408 | 15,000 | 7.5 K to 15 K (+100.00 %) |
| Nov 28 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 9.75 | 7,500 | 73,143 | 7,500 | 0 to 7.5 K |
| Nov 28 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Buy | P | 9.75 | 7,500 | 73,143 | 7,500 | 0 to 7.5 K |
| Sep 12 2018 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Buy | P | 3.23 | 50,000 | 161,340 | 215,000 | 165 K to 215 K (+30.30 %) |
| Sep 12 2018 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Buy | P | 3.28 | 50,000 | 164,210 | 165,000 | 115 K to 165 K (+43.48 %) |
| Aug 27 2018 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Buy | P | 2.82 | 100,000 | 282,320 | 115,000 | 15 K to 115 K (+666.67 %) |
| May 11 2018 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Option Exercise | A | 2.11 | 50,000 | 105,500 | 50,000 | |
| Mar 16 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Option Exercise | A | 9.50 | 10,000 | 95,000 | 10,000 | |
| Jan 26 2018 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Option Exercise | A | 4.49 | 150,000 | 673,500 | 150,000 | |
| Jan 09 2018 | EIGR | Eiger BioPharmaceu ... | Mayer Eldon C. III | Director | Option Exercise | A | 13.70 | 25,000 | 342,500 | 25,000 | |
| Feb 06 2017 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP & Chief Commerc ... | Option Exercise | A | 2.11 | 50,000 | 105,500 | 50,000 | |
| Oct 11 2016 | RIGL | RIGEL PHARMACEUTIC ... | Mayer Eldon C. III | EVP &Chief Commerci ... | Option Exercise | A | 3.92 | 300,000 | 1,176,000 | 300,000 |
Page: 1